This grant is to provide support for the Statistical Office of the Eastern Cooperative Oncology Group (ECOG). The Statistical Office, under the direction of the ECOG Group Statistician, collaborates on the design, monitoring and analysis of all clinical trials conducted by ECOG. The Statistical Office works with the ECOG Data Management Office and together, the two offices comprise the ECOG Statistical Center. The statisticians are involved in all aspects of ECOG's activities and also conduct an active research program. Relevance: The primary goal of the ECOG Operations office is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Kaplan, David; Sun, Zhuoxin; Tallman, Martin S et al. (2014) Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70. Cytometry A 85:798-808
Wilson, Melissa A; Zhao, Fengmin; Letrero, Richard et al. (2014) Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 20:3328-37
Burtness, Barbara; Powell, Mark; Catalano, Paul et al. (2014) Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol :
Pillai, Rathi N; Aisner, Joseph; Dahlberg, Suzanne E et al. (2014) Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). Cancer Chemother Pharmacol 74:177-83
Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B et al. (2014) Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34:376-84
Dahlberg, Suzanne E; Schiller, Joan H; Bonomi, Philip B et al. (2013) Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol 8:1121-7
Go, Ronald S; Lee, Sandra J; Shin, Donghoon et al. (2013) ECOG phase II trial of graded-dose peginterferon ?-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res 19:6597-604
Argiris, Athanassios; Ghebremichael, Musie; Gilbert, Jill et al. (2013) Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 31:1405-14
Tevaarwerk, Amye J; Gray, Robert J; Schneider, Bryan P et al. (2013) Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119:1140-8

Showing the most recent 10 out of 447 publications